Outlook into Circulating Tumor Cells: Isolation & Detection Patent Landscape 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Circulating Tumor Cells: Isolation & Detection Patent Landscape" report has been added to ResearchAndMarkets.com's offering.

This IP study includes selection and description of key patents. The key patent analysis includes the legal state of the family for each of the main territories, the number of received citations, the review of the main claim(s), the description of interesting features about the innovation disclosures and relevant figures illustrating how the innovation works. The description also contains information about the fact that the patent family was involved in a patent litigation in the USA.

Moreover, the report also includes an Excel database with the >1,680 patents analyzed in this study. This useful patent database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to the original documents, priority dates, titles, abstracts, patent assignees, each patent's current legal status and segmentation to which it belongs.

Report's Key Features

  • PDF with > 160 slides
  • Excel file > 5,500 patents
  • IP trends, including time-evolution of published patents, and countries of patent filings
  • Patents' legal status
  • Ranking of main patent assignees
  • Key players' IP position and relative strength of their patent portfolios
  • Summary of the IP related to the physical isolation: size, deformability, electrical charges or density.
  • Summary of the IP related to the biological isolation: positive or negative enrichment.
  • Summary of the IP related to the CTC detection: nucleic acid, protein or functional assay.
  • Analysis of patent litigations and review of key patents.
  • Excel database containing all patents analyzed in the report, including biological and physical isolation and detection segmentations

The analysis of the time evolution of patent publications shows that CTC isolation and detection started to be investigated in the late 1990s with a first patent filed in 1995 by Dendreon (company acquired by San Power in 2017). Until 2009, there is a latent period, even if big pharmaceutical companies and some academics begin to take interest in CTC. From 2010 to 2016, an acceleration is observed with big newcomers (Nestl, Samsung, Siemens or Hitachi Chemicals). In 2016-2017, publications stagnated despite the arrival of new players. The main patent assignees are US industrial players that develop an international intellectual property strategy. Europe and China are the main countries of protection, which appear to be strategic territories for these applicants.

Analysis by segment

CTC could be isolated and detected using various methods. Therefore, a technological segmentation was made in this IP landscape, as follows:

  • CTC isolation: Efficient enrichment of CTC can be achieved by approaches that exploit differences between tumor cells and blood cells, including the differential expression of cell surface proteins or distinct physical properties of the cells.
    • Physical isolation: Assays are based on CTC physical characteristics including size, deformability, density and electrical charge.
    • Biological isolation: It is protein-based methods which rely mainly on specific markers that are detected by antibodies or by other particles like aptamers. The sample can be enriched in desired cells (positive isolation) or depleted in unwanted cells (negative isolation).
  • CTC detection: Once CTC concentration is increased, for an unambiguous isolation of CTC, detection methods are necessary.
    • Nucleic Acid: DNA or RNA are identified by RT-PCR, FISH, etc.
    • Protein: Surface markers are detected by antibodies (anti-EpCam, Anti-Cytokeratin, etc.) and visualized by microscopy, FACS, etc.
    • Functional assays: EPISPOT or invasion assays.
  • Other technologies: Raman spectroscopy, surface acoustic waves or the use of virus or phagocytic cells, etc.
  • Medical devices: In vivo apparatus like an implantable device or apheresis.

Key Topics Covered:


  • Definition of a circulating tumor cell
  • Scope of the report
  • Key features of the report
  • Objectives of the report


  • Patent search, selection and analysis
  • Search strategy
  • Terminologies for patent analysis
  • Strength and blocking potential




  • Time evolution of patent publications
  • Countries of patent filings
  • Time evolution by country of filing
  • Ranking of most prolific patent applicants
  • Current legal status of the main players
  • Patent legal status of the corpus
  • Mapping of main current IP holders
  • Patenting activity of IP leading companies
  • Time evolution of main patent assignees
  • Newcomers
  • Main IP collaborations
  • Main acquisitions


  • IP leadership of patent applicants
  • IP blocking potential of patent applicants
  • Strength index of patent portfolios


  • Patent citation analysis
  • Key patent families
  • Main oppositions on EP patents
  • Main granted patents expired or lapsed in 2019
  • Main granted patents that will expire in 2020
  • Main granted patents that will expire in 2021


  • Definition
  • Main assignees by technology
  • Main assignees by IP position and technology
  • CTC isolation: physical properties
  • CTC isolation: biological properties
  • CTC detection and characterization
  • CTC isolation and detection: Other methods and medical devices
  • CTC stabilization



Companies Mentioned

  • Abbott
  • Abbvie
  • Arkray
  • Astellas
  • Aviva Biosciences
  • Becton Dickinson
  • Biocept
  • Celsee
  • Creatv Microtech
  • Cytogen
  • Cyttel Biosciences
  • Decipher Bioscience
  • Epic Sciences
  • Eutropics Pharmaceuticals
  • Gencurix
  • Genobio
  • Gilupi
  • GPB Scientific
  • Hitachi Chemical
  • Illumina
  • Janssen Diagnostics
  • Jusbio Sciences
  • Konica Minolta
  • Lung Life AI
  • Menarini Silicon Biosystems
  • Nestle
  • Rarecyte
  • Roche
  • Genentech
  • Sumitomo
  • Surexam
  • Tosoh

For more information about this report visit https://www.researchandmarkets.com/r/rsfp1k


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900